Pemetrexed for the treatment of non-small cell lung cancer.

abstract：INTRODUCTION:Benign prostate hyperplasia (BPH) is one of the most prevalent diseases in aging men. It may adversely affect quality-of-life due to the presence of low urinary tract symptoms (LUTS) and its effects on sexuality. AREAS COVERED:The impact of α1-blockers, 5α-reductase inhibitors (5-ARI), and phosphodiestera...

journal_title：Expert opinion on pharmacotherapy

authors： La Vignera S,Aversa A,Cannarella R,Condorelli RA,Duca Y,Russo GI,Calogero AE

更新日期：2020-09-09 00:00:00

abstract：INTRODUCTION:Treatment options for relapsed ovarian cancer have increased over the decade with the addition of targeted agents, such as PARP inhibitors and antiangiogenic agents. Bevacizumab, a monoclonal antibody binding vascular endothelial growth factor (VEGF), was the first anti-angiogenic agent to be incorporated ...

journal_title：Expert opinion on pharmacotherapy

authors： Orbegoso C,Marquina G,George A,Banerjee S

更新日期：2017-10-01 00:00:00

abstract：INTRODUCTION:Following more than 20 years of Interferon (IFN)-based treatment for hepatitis C virus (HCV), the understanding of viral life cycle led to the development of new antiviral drugs directly targeting HCV replication steps. Daclatasvir (DCV) is a potent inhibitor of non-structural NS5A HCV protein with pangeno...

journal_title：Expert opinion on pharmacotherapy

authors： Degasperi E,Aghemo A,Colombo M

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Prescription omega-3-acid ethyl esters (P-OM3) have been used as adjunctive therapy to statin drugs in patients with mixed hyperlipidemia. OBJECTIVE:To assess the effect of concomitant administration of 4 g P-OM3 on the steady-state pharmacokinetics of the maximum recommended daily dose of atorvastatin (80 ...

journal_title：Expert opinion on pharmacotherapy

authors： Di Spirito M,Morelli G,Doyle RT,Johnson J,McKenney J

更新日期：2008-12-01 00:00:00

abstract：INTRODUCTION:Despite the availability of numerous anti-diabetes drugs and treatment guidelines, many patients with type 2 diabetes mellitus (T2DM) do not reach recommended targets for glycemic control. There remains an unmet need for effective and well-tolerated anti-diabetes agents that can be used as monotherapy or i...

journal_title：Expert opinion on pharmacotherapy

authors： Jahagirdar V,Barnett AH

更新日期：2014-11-01 00:00:00

abstract：:Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was recently approved by the FDA for the treatment of advanced breast cancer. It shows synergy with trastuzumab, and has demonstrated clinical activity in trastuzumab-resistant tumour. This paper reviews the drug development of lapati...

journal_title：Expert opinion on pharmacotherapy

authors： Mukherjee A,Dhadda AS,Shehata M,Chan S

更新日期：2007-09-01 00:00:00

abstract：INTRODUCTION:Many patients with type 2 diabetes mellitus (T2DM) fail to achieve the desired A1c goal because the antidiabetic medications used do not correct the underlying pathophysiologic abnormalities and monotherapy is not sufficiently potent to reduce the A1c to the 6.5 - 7.0% range. Insulin resistance and islet (...

journal_title：Expert opinion on pharmacotherapy

authors： Triplitt C,Solis-Herrera C,Cersosimo E,Abdul-Ghani M,Defronzo RA

更新日期：2015-01-01 00:00:00

abstract：:Introduction: The current recommendations of chronic obstructive pulmonary disease (COPD) suggest to escalate from inhaled corticosteroid/long-acting β2-adrenoceptor agonist (ICS/LABA) treatment to triple therapy in patients experiencing persistent breathlessness, exercise limitation, or exacerbation. The addition of ...

journal_title：Expert opinion on pharmacotherapy

authors： Ritondo BL,Puxeddu E,Calzetta L,Cazzola M,Rogliani P

更新日期：2020-11-11 00:00:00

abstract：INTRODUCTION:Epilepsy is a serious and common chronic neurological disease with an urgent need for novel treatment options, because 30% of all epilepsy patients do not respond to currently available drugs. Retigabine/Ezogabine (RTG) is a third-generation antiepileptic drug (AED) with a novel mechanism of action. It enh...

journal_title：Expert opinion on pharmacotherapy

authors： Orhan G,Wuttke TV,Nies AT,Schwab M,Lerche H

更新日期：2012-08-01 00:00:00

abstract：INTRODUCTION:Breast cancer is a common, life-threatening disease among women. Contemporary hormonal therapy with third-generation aromatase inhibitors for estrogen-receptor-positive breast cancers in postmenopausal women is still facing the challenge of interpatient variability in therapeutic response and intensity of ...

journal_title：Expert opinion on pharmacotherapy

authors： Turkistani A,Marsh S

更新日期：2012-06-01 00:00:00

abstract：:Injectable and absorbable contrast media for the use in radiology, all of which contains iodine as an essential component, has been, and continues to be, one of the main sources of agents which cause hospital-acquired renal failure. Although numerous methods have been explored to prevent renal contrast damage, radioco...

journal_title：Expert opinion on pharmacotherapy

authors： Mintz EP,Gruberg L

更新日期：2003-05-01 00:00:00

abstract：INTRODUCTION:Meropenem-vaborbactam is a new beta-lactam/beta-lactamase inhibitor combination that combines a carbapenem antibiotic with a first-in-class, boronic acid pharmacophore, serine beta-lactamase inhibitor which has potent inhibitory activity against class A carbapenemases, especially Klebsiella pneumoniae carb...

journal_title：Expert opinion on pharmacotherapy

authors： Wu G,Cheon E

更新日期：2018-09-01 00:00:00

abstract：OBJECTIVE:To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years). RESEARCH DESIGN AND METHODS:Post hoc analysis o...

journal_title：Expert opinion on pharmacotherapy

authors： Hargarter L,Bergmans P,Cherubin P,Keim S,Conca A,Serrano-Blanco A,Bitter I,Bilanakis N,Schreiner A

更新日期：2016-06-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Treatment options for amyloidosis and polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome have rapidly increased in the past years, but many patients are diagnosed late in the disease course and do not receive state-of-the art therapy. AREAS COVERED IN THI...

journal_title：Expert opinion on pharmacotherapy

authors： Chee CE,Dispenzieri A,Gertz MA

更新日期：2010-06-01 00:00:00

abstract：INTRODUCTION:Cardiovascular disease is a major cause of death, and hypercholesterolemia is a major risk factor. Statins, with simvastatin among the most widely used, have ample evidence demonstrating prevention of cardiovascular events and mortality. Ezetimibe is effective at improving serum lipids in combination with ...

journal_title：Expert opinion on pharmacotherapy

authors： Gryn SE,Hegele RA

更新日期：2015-06-01 00:00:00

abstract：INTRODUCTION:Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of the central nervous system involving inflammation, chronic demyelination and axonal loss. MS affects more than 2 million people worldwide. AREAS COVERED:This article aims to summarize the findings from two pivotal 2-year, randomized, do...

journal_title：Expert opinion on pharmacotherapy

authors： Havrdova E,Hutchinson M,Kurukulasuriya NC,Raghupathi K,Sweetser MT,Dawson KT,Gold R

更新日期：2013-10-01 00:00:00

abstract：:One vaccine designed to prevent cancer by preventing a precursor infection is already in common use, and at least one more is in the latter stages of clinical development. These vaccines are part of a new era of cancer immunoprophylaxis. Several further vaccines are in preclinical and clinical development, targeted at...

journal_title：Expert opinion on pharmacotherapy

authors： Frazer I

更新日期：2004-12-01 00:00:00

abstract：INTRODUCTION:Bipolar disorder is characterized by mood instability, which can be challenging to manage. First-line pharmacological approaches usually involve lithium, anticonvulsants and antipsychotics. Over the past fifteen years, several second-generation antipsychotics have demonstrated benefits for various phases o...

journal_title：Expert opinion on pharmacotherapy

authors： Janicak PG,Rado JT

更新日期：2012-08-01 00:00:00

abstract：:This editorial considers the use of the first selective oral renin inhibitor, aliskiren, in reducing angiotensin (Ang) II reactivation or aldosterone (ALDO) escape during renin-angiotensin-aldosterone system (RAAS) inhibition. RAAS blockade with angiotensin converting enzyme inhibitors (ACEIs) and/or angiotensin recep...

journal_title：Expert opinion on pharmacotherapy

authors： Athyros VG,Mikhailidis DP,Kakafika AI,Tziomalos K,Karagiannis A

更新日期：2007-04-01 00:00:00

abstract：INTRODUCTION:Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepi...

journal_title：Expert opinion on pharmacotherapy

authors： Striano P,Belcastro V

更新日期：2013-07-01 00:00:00

abstract：INTRODUCTION:Glioblastoma, the most common malignant brain tumor, exhibits a poor prognosis with little therapeutic progress in the last decade. Novel treatment strategies beyond the established standard of care with temozolomide-based radiotherapy are urgently needed. AREAS COVERED:We reviewed the literature on gliob...

journal_title：Expert opinion on pharmacotherapy

authors： Seystahl K,Gramatzki D,Roth P,Weller M

更新日期：2016-06-01 00:00:00

abstract：INTRODUCTION:Radioiodine [RAI]-resistant advanced and progressive differentiated thyroid cancer [DTC], although rare, constitutes a real challenge as its prognosis is poor and available therapeutic options, until now, have been limited. Discovery of a crucial role of distinct tyrosine kinases in DTC pathogenesis opened...

journal_title：Expert opinion on pharmacotherapy

authors： Krajewska J,Kukulska A,Jarzab B

更新日期：2016-08-01 00:00:00

abstract：:A randomized Phase III trial tested the efficacy of pemetrexed as maintenance treatment in patients with advanced non-small-cell lung cancer (NSCLC) who were without progression after completing four cycles of first-line platinum-based chemotherapy. The primary endpoint of the trial was progression-free survival (PFS)...

journal_title：Expert opinion on pharmacotherapy

authors： Gridelli C,Di Maio M

更新日期：2010-02-01 00:00:00

abstract：INTRODUCTION:Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. AREAS COVERED:This review discusses ...

journal_title：Expert opinion on pharmacotherapy

authors： Daniels LM,Kufel WD

更新日期：2018-11-01 00:00:00

abstract：INTRODUCTION:Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and supraventricular arrhythmias. The Cardiac Arrhythmia Suppression Trial (CAST), conducted to test...

journal_title：Expert opinion on pharmacotherapy

authors： Apostolakis S,Oeff M,Tebbe U,Fabritz L,Breithardt G,Kirchhof P

更新日期：2013-02-01 00:00:00

abstract：INTRODUCTION:Hypertension is highly prevalent in patients with end-stage kidney disease on hemodialysis and is often not well controlled. Blood pressure (BP) levels before and after hemodialysis have a U-shaped relationship with cardiovascular and all-cause mortality. Although antihypertensive drugs are recommended for...

journal_title：Expert opinion on pharmacotherapy

authors： Maruyama T,Takashima H,Abe M

更新日期：2020-07-01 00:00:00

abstract：:This article reviews the evidence supporting different somatic treatment strategies in the acute and maintenance treatment phases of bipolar disorder. Bipolar affective disorder is a chronic disorder with a life time incidence of 0.3 - 1.5/100 [1]. Severe affective disorder is associated with a risk of completed suici...

journal_title：Expert opinion on pharmacotherapy

authors： Watson S,Young AH

更新日期：2001-04-01 00:00:00

abstract：INTRODUCTION:Phosphodiesterase type 5 inhibitors (PDE5-i) are used for the oral treatment of erectile dysfunction (ED). Since the launch of sildenafil more than 15 years ago, new molecules have become available. At present, in addition to tadalafil and vardenafil, there are three other drugs, udenafil, avanafil and mir...

journal_title：Expert opinion on pharmacotherapy

authors： Bruzziches R,Francomano D,Gareri P,Lenzi A,Aversa A

更新日期：2013-07-01 00:00:00

abstract：BACKGROUND:Management of a number of significant viral pathogens in transplant recipients remains challenging. OBJECTIVES:To define an optimal antiviral approach to the management of cytomegalovirus (CMV), human herpes virus-6 (HHV-6), Epstein-Barr (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), ...

journal_title：Expert opinion on pharmacotherapy

authors： Sun HY,Singh N

更新日期：2008-10-01 00:00:00

abstract：BACKGROUND:Dexmethylphenidate is a single-isomer stimulant medication approved for the treatment of attention deficit hyperactivity disorder (ADHD). Single-isomer drugs have the potential for decreased undesired effects and improved therapeutic efficacy. Stimulant medications have been the mainstay treatments for ADHD ...

journal_title：Expert opinion on pharmacotherapy

authors： Coury D

更新日期：2009-11-01 00:00:00